Research programme: COPD therapeutics - AstraZeneca

Drug Profile

Research programme: COPD therapeutics - AstraZeneca

Alternative Names: AZD2743; AZD6067; AZD6213; AZD7420; AZD7928

Latest Information Update: 13 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors; Granulocyte macrophage colony stimulating factor antagonists; Interleukin receptor antagonists; Matrix metalloproteinase 12 inhibitors; Peptide hydrolase inhibitors; Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Jul 2010 Preclinical development is ongoing
  • 18 Jan 2008 Preclinical development is ongoing
  • 02 Feb 2006 Preclinical trials in Chronic obstructive pulmonary disease in European Union (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top